New Study: V̇-Com™ Reducing Inspiratory Positive Airway Pressure

KPAP Efficacy and Comfort Trial

Perfecting the science of precise pressure.

Introducing

KPAP™(Kairos Positive Airway Pressure)

For the first time, a radically new pressure algorithm demonstrates improved patient comfort by delivering the optimal inspiratory and expiratory pressure...
at the right time.

KPAP™ and masks have not been cleared by FDA and will be the subject of a marketing submission. It is not currently available for sale in USA.

Previous efforts to address the condition while making therapy comfortable and tolerable have fallen short.

Normal

Apnea

CPAP Mask

BiPAP

C-FLEX

EPR

  • Lowering IPAP
    makes inspiratory pattern and flow more like a patient’s normal respiration.


  • Lowering EPAP
    reduces expiratory work of breathing.


  • Yet returning pressure to optimal levels when appropriate.

We need to make therapy be more like natural breathing.

Optimizing pressure
delivers a better way.

Timing is everything.

KPAP™

  • Inspiration: Pressure dropped 2cm and then 3cm H2O yielding a pressure 5cm H2O below therapeutic pressure.
  • Expiration: Pressure down at initiation of expiration and stays down through most of the expiratory cycle.
  • End Expiration: Pressure returned to therapeutic levels to assure optimal pharyngeal patency and lung volume.

KPAP™ preferred to CPAP by virtually all patients

KPAP™ Comfort Study Results

  • 150 patients with recently diagnosed, untreated OSA with an AHI>10.
  • Prior to initiation of PAP were exposed to and asked to compare for comfort:
    • CPAP at 9 and 13cm H2O
    • KPAP™ at 9 and 13cm H2O with various pressure drops
  • Outcome:
    • Patient selects each time whether CPAP or KPAP™ is more comfortable in blinded manner

KPAP™ was More Comfortable than CPAP for the Vast Majority of Patients

KPAP™ delivers equivalent therapeutic efficacy to standard CPAP

KPAP™ Efficacy Trial

  • 50 patients with documented OSA on stable APAP with >6 hours per night adherence.
  • Reported to the sleep lab for a full night PSG. In random order the patient slept:
    • Half the night on CPAP set at the P95 pressure determined from the PAP device at home.
    • Half the night on KPAP™ set at the same P95 with a 2cm then 3cm H2O (total 5 cm H2O) drop during inspiration and a return to the P95 pressure approximately half way through expiration.
  • Comparisons of CPAP versus XPAP included:
    • AHI 3a (3% fall in Sp02 or arousal to score hypopneas)
    • AHI 4 (4% fall in Sp02 to score hypopneas)
    • AHI in REM and NREM sleep
    • AHI supine and lateral

KPAP™ was Equivalent to CPAP when all Sleep Stages and Positions are Combined

In conclusion:

  • KPAP™ has the same efficacy in treating OSA as standard CPAP despite dropping the pressure by 5cm H2O.
  • Patients initiating PAP therapy virtually all found KPAP™ more comfortable than CPAP.
  • We now need to conduct adherence trials comparing KPAP™ (with auto-titration) to standard APAP.
    • 6-week randomized crossover trial with adherence as the primary outcome.

Want to learn more?

Click here >

Device shown for illustrative purposes only
KPAP™ and masks have not been cleared by FDA and will be the subject of a marketing submission. It is not currently available for sale in USA.